Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy

This study tests whether adding radiotherapy (radiation treatment) to ongoing treatment can improve outcomes in patients with metastatic esophageal cancer (squamous cell type) who have already responded well to first-line immunotherapy plus chemotherapy. **You may be eligible if...** - You are 18 or older - You have squamous cell carcinoma of the esophagus at stage IVb (widely spread), or recurrent after prior curative treatment - You have responded to 2 to 4 cycles of chemotherapy combined with an immunotherapy (PD-1 inhibitor) - Your overall health is good (ECOG performance status 0 or 1) - Your blood counts and organ function are within normal limits **You may NOT be eligible if...** - You have a history of another cancer (except some skin cancers or cervical cancer in situ) - You received surgery, chemotherapy, or other cancer treatment before joining this study - You have an active infection or had a recent heart attack, stroke, or major surgery in the past 6 months - You have an allergy to chemotherapy drugs or a history of serious autoimmune disease - You are enrolled in another trial or within 4 weeks of leaving one Talk to your doctor to see if this trial is right for you.